Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-044336
Filing Date
2025-05-15
Accepted
2025-05-15 16:57:48
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0242061-10q_ostherap.htm   iXBRL 10-Q 750092
2 CERTIFICATION eea024206101ex31-1_ostherap.htm EX-31.1 9501
3 CERTIFICATION eea024206101ex31-2_ostherap.htm EX-31.2 9647
4 CERTIFICATION eea024206101ex32_ostherap.htm EX-32 6072
  Complete submission text file 0001213900-25-044336.txt   5868987

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE osti-20250331.xsd EX-101.SCH 60425
6 XBRL CALCULATION FILE osti-20250331_cal.xml EX-101.CAL 29312
7 XBRL DEFINITION FILE osti-20250331_def.xml EX-101.DEF 285861
8 XBRL LABEL FILE osti-20250331_lab.xml EX-101.LAB 513504
9 XBRL PRESENTATION FILE osti-20250331_pre.xml EX-101.PRE 306165
71 EXTRACTED XBRL INSTANCE DOCUMENT ea0242061-10q_ostherap_htm.xml XML 628589
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42195 | Film No.: 25955026
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)